Medigen Vaccine Biologics (ROCO:6547) Owner Earnings per Share (TTM): -0.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
68 GF Score
Price NT$59.70
GF Value NT$55.20
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Owner Earnings per Share (TTM)?

Medigen Vaccine Biologics ROCO:6547 -1.65% 68 Owner Earnings per Share (TTM) is -0.61 as of Jun. 2026. GuruFocus rates ROCO:6547 with a GF Score™ of 68/100 and a GF Value™ of NT$55.20 (Fairly Valued). The stock has 4 warning signs investors should review. Among 213 Biotechnology companies, Medigen Vaccine Biologics ranks worse than 469483.1% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Medigen Vaccine Biologics's Owner Earnings per Share (TTM) ended in Jun. 2026 was NT$-0.61. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Medigen Vaccine Biologics's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Medigen Vaccine Biologics was 143.33. The lowest was 90.25. And the median was 110.64.


ROCO:6547's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 23.78
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Medigen Vaccine Biologics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was NT$0.07. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-0.51. It's PE Ratio (TTM) ratio for today is At Loss.

Medigen Vaccine Biologics's EPS without NRI for the three months ended in Jun. 2026 was NT$0.07. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-0.51. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by FactSet. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Medigen Vaccine Biologics Owner Earnings per Share (TTM) Related Terms


Medigen Vaccine Biologics Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Owner Earnings per Share (TTM) Chart

Medigen Vaccine Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 -4.01 -1.79 -0.42 -0.51

Medigen Vaccine Biologics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.33 -0.47 -0.60 -0.69

ROCO:6547 vs VRTX, REGN, MRNA: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Medigen Vaccine Biologics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's Price-to-Owner-Earnings falls into.


ROCO:6547
68GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Medigen Vaccine Biologics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -166.8
Depreciation, Depletion and Amortization 147.5
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 141.9
Change In Working Capital -85.5
Shares Outstanding (Diluted Average) 328.7

1. Start with "Net Income" from income statement. Medigen Vaccine Biologics's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-166.8 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Medigen Vaccine Biologics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was NT$147.5 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Medigen Vaccine Biologics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = NT$141.9 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Medigen Vaccine Biologics's 5-Year Average Maintenance Capital Expenditure = NT$141.9 Mil

5. "Change In Working Capital" is from cashflow statement. Medigen Vaccine Biologics's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-85.5 Mil.
Note: GuruFocus' Change in Working Capital is provided by FactSet. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Medigen Vaccine Biologics's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 328.749 Mil.

Medigen Vaccine Biologics's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -166.771 +147.533+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-141.8574+-85.503)/328.749
=-0.61

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=59.70/-0.61
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -0.61 mean?
Medigen Vaccine Biologics (ROCO:6547) has a Owner Earnings per Share (TTM) of -0.61 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Medigen Vaccine Biologics. According to the industry distribution chart, Medigen Vaccine Biologics ranks #999999 out of 213 companies in the Biotechnology industry.
Is Medigen Vaccine Biologics' Owner Earnings per Share (TTM) too high?
Medigen Vaccine Biologics' current Owner Earnings per Share (TTM) is -0.61. Based on the distribution chart, Medigen Vaccine Biologics ranks #999999 out of 213 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Vaccine Biologics has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Owner Earnings per Share (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #999999 out of 213 companies for Owner Earnings per Share (TTM). This places Medigen Vaccine Biologics in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 23.78, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Medigen Vaccine Biologics. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 23.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current Owner Earnings per Share (TTM) is -0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Fairly Valued. The stock's GF Value™ is NT$55.20, compared to a current price of NT$59.70 — trading 8.2% above its estimated fair value. The current Owner Earnings per Share (TTM) is -0.61. Medigen Vaccine Biologics' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Owner Earnings per Share (TTM) is -0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be overvalued. The current stock price of NT$59.70 is trading 8.2% above its estimated GF Value™ of NT$55.20. GuruFocus considers Medigen Vaccine Biologics to be Fairly Valued.

Key valuation signals for ROCO:6547:

  • Owner Earnings per Share (TTM): -0.61
  • GF Value™: NT$55.20 vs. price of NT$59.70 (8.2% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score

Get the complete analysis for ROCO:6547

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.70
Price
NT$55.20
GF Value